Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
27 Junho 2023 - 5:30PM
Business Wire
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced it will host a conference call and
webcast on Wednesday, June 28, at 1:30 p.m. Pacific Time (4:30 p.m.
Eastern Time) to report results for its fiscal year 2023 ended
March 31, 2023 and provide a corporate update.
Event: Vistagen Fiscal Year 2023 Corporate Update
Conference Call Date: Wednesday, June 28, 2023 Time:
1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) US Dial-in (Toll
Free): 1-877-407-9716 TOLL/International Dial-in:
1-201-493-6779 Conference ID: 13739679 Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1622868&tp_key=e466ec0ec7
An audio webcast of the conference call will also be available
via the link provided above. Participants should access this
webcast site 10 minutes before the start of the call. In addition,
a telephone playback of the call will be available after
approximately 5:00 p.m. Pacific Time on Wednesday, June 28, 2023.
To listen to the replay, call toll free 1-844-512-2921 within the
United States or 1-412-317-6671 when calling internationally
(toll). Please use the replay access ID number: 13739679.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available for
treatment of anxiety, depression and multiple CNS disorders.
Vistagen’s pipeline includes six product candidates, including
fasedienol (PH94B), itruvone (PH10) and three additional
investigational agents belonging to a new class of drugs known as
pherines, in addition to AV-101, which is an oral antagonist of the
N-methyl-D-aspartate receptor (NMDAR). Pherines, which are
administered as nasal sprays, are designed with a novel rapid-onset
mechanism of action that activates chemosensory neurons in the
nasal passages and can beneficially impact key neural circuits in
the brain without systemic uptake or direct activity on CNS neurons
in the brain. Vistagen is passionate about transforming mental
health care and redefining what is possible in the treatment of
anxiety, depression and several other CNS disorders. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230627404546/en/
Investors Mark A. McPartland Senior Vice President,
Investor Relations (650) 577-3606 markmcp@vistagen.com
Media Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024